Wolfgang Miesbach: Translating Gene Therapy into Haemophilia Care at EHA 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Honoured to be speaking at EHA 2026 this Friday, 12 June in the ‘Gene engineering and therapy’ session.
In ‘Translating Genetic Innovation into Haemophilia Care’ (P141-2), I’ll explore how three decades of gene therapy development are reshaping not just treatment, but how care itself is organised — from the structure of treatment centres to the way we follow patients across their lifetimes.
Haemophilia has long been a proving ground for genetic medicine, and the lessons here ripple out to many other conditions.
I’ll also reflect on a sobering reality: some gene therapies are being pulled from the market not because they failed patients, but because the business model did.
The future of genetic medicine may depend less on what we can cure than on what our systems are willing to pay for.”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome